Celgene pays $177.25mm up front for major OncoMed stem cell therapy deal
Celgene Corp. signed a major cancer stem cell (CSC) therapy deal with OncoMed Pharmaceuticals Inc. that could be worth over $3bn if all milestones are realized.
- Gene Therapy, Cell Therapy
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.